INTEGRICHAIN


Associated tags: Patient, Nordic Capital, Science

Locations: PHILADELPHIA, PA, INDIA

Registration Opens for Access Insights Conference 2024 Co-Hosted by IntegriChain and Blue Fin Group

Retrieved on: 
Tuesday, April 9, 2024
Conference, Mayflower Hotel, Pharmaceutical industry

PHILADELPHIA, April 9, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that registration is now open to all pharma manufacturers for the Access Insights Conference 2024, co-hosted with Blue Fin Group. The Access Insights Conference will be held October 14-16, 2024, at The Mayflower Hotel, Autograph Collection, in Washington, DC.

Key Points: 
  • PHILADELPHIA, April 9, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that registration is now open to all pharma manufacturers for the Access Insights Conference 2024, co-hosted with Blue Fin Group.
  • The Access Insights Conference will be held October 14-16, 2024, at The Mayflower Hotel, Autograph Collection, in Washington, DC.
  • Keynoting the conference will be Bill Roth, General Manager and Managing Partner of Blue Fin Group and a recognized expert on business model development in healthcare.
  • We are excited to co-host this year's conference again with our esteemed colleagues from Blue Fin Group, and together we will deliver high-value information and insights to our attendees who are commercializing important innovative therapies."

Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board

Retrieved on: 
Wednesday, February 28, 2024
Public policy, Gilead Sciences, EVP, Entrepreneurship, Patient, Knowledge, HIV, Hepatitis C, Pharma, Pharmaceutical industry

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.

Key Points: 
  • PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.
  • "We are thrilled to have an industry icon of Jim's caliber lead our board as our company matures," said Josh Halpern , Co-Founder and CEO of IntegriChain.
  • The Board is enthusiastic about adding further expertise to build upon the Company's leadership and support the expansion of its product offerings," said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors and Board Member of IntegriChain.
  • "I am honored to join the IntegriChain board at this pivotal moment," said Meyers.

IntegriChain Appoints Seasoned Executive to Lead Data Business for Pharma Distribution and Patient Access

Retrieved on: 
Tuesday, January 2, 2024
Uccello, Growth, Senior

PHILADELPHIA, Jan. 2, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jeff Uccello as Senior Vice President and General Manager of Data Solutions. Uccello is a seasoned pharma data executive with more than 20 years of experience across a wide range of commercialization data and analytics and business leadership roles. He will lead IntegriChain's resurging Data business, including the highly differentiated and industry-leading Channel Data solutions and the innovative Patient Access solutions as well as their integration into key ICyte Contracts & Pricing and Gross-to-Net workflows for modeling and decision-making.

Key Points: 
  • Uccello is a seasoned pharma data executive with more than 20 years of experience across a wide range of commercialization data and analytics and business leadership roles.
  • He will lead IntegriChain's resurging Data business, including the highly differentiated and industry-leading Channel Data solutions and the innovative Patient Access solutions as well as their integration into key ICyte Contracts & Pricing and Gross-to-Net workflows for modeling and decision-making.
  • "As the Pharma industry faces new headwinds in net revenue optimization, our Data solutions and analytics are more critical now than ever across all key stakeholders in commercialization and access," said IntegriChain Co-Founder and CEO, Josh Halpern .
  • "Jeff's deep roots in commercializing pharma data solutions and analytics will be vital to the long-term growth and success of our Data business.

IntegriChain Announces Close of Nordic Capital Majority Investment

Retrieved on: 
Tuesday, December 19, 2023
Entrepreneurship, Investment, Nordic Capital, Accel-KKR

PHILADELPHIA, Dec. 19, 2023 /PRNewswire/ -- IntegriChain today announced the close of an investment agreement whereby Nordic Capital has acquired the majority stake in IntegriChain. IntegriChain's integrated ICyte Platform helps pharma manufacturers connect the commercial, financial, and operational dimensions of drug commercialization, access, and profitability. Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma, acquired the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.

Key Points: 
  • PHILADELPHIA, Dec. 19, 2023 /PRNewswire/ -- IntegriChain today announced the close of an investment agreement whereby Nordic Capital has acquired the majority stake in IntegriChain.
  • IntegriChain's integrated ICyte Platform helps pharma manufacturers connect the commercial, financial, and operational dimensions of drug commercialization, access, and profitability.
  • Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma, acquired the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
  • Nordic Capital has unique experience at the crossroads of Pharma, healthcare technology, and payments technology.

IntegriChain and Blue Fin Group Pharma Trade and Distribution Experts to Speak at Informa Trade & Channel Strategies

Retrieved on: 
Tuesday, December 5, 2023
Trade, Partner (business rank), Wholesaling, Informa, Pulse, System, Pharma, PBM

PHILADELPHIA, Dec. 5, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical strategy expert Bill Roth , General Manager and Managing Partner, Blue Fin Group, an IntegriChain Company, will be the keynote speaker at Informa's Trade & Channel Strategies conference.

Key Points: 
  • PHILADELPHIA, Dec. 5, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical strategy expert Bill Roth , General Manager and Managing Partner, Blue Fin Group, an IntegriChain Company, will be the keynote speaker at Informa's Trade & Channel Strategies conference.
  • In addition, distribution experts David Weiss , IntegriChain Vice President of Industry Solutions, and Jason Bogroff , Blue Fin Group Partner, will speak at the event.
  • IntegriChain is a sponsor of the conference, which runs December 11 through 13 in Philadelphia.
  • Details of the highlighted sessions are as follows.

Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access

Retrieved on: 
Wednesday, November 8, 2023
Science, Accel-KKR, Entrepreneurship, Growth, Partnership, Patient, Pharma, Fine chemical, Pharmaceutical industry, Financial adviser, Nordic Capital, Health care

IntegriChain delivers pharma's only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy.

Key Points: 
  • IntegriChain delivers pharma's only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy.
  • Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
  • IntegriChain's integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability.
  • Josh Halpern, Co-Founder and CEO of IntegriChain, said: "We're pleased to have Nordic Capital as a new partner to support us on our journey.

Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access

Retrieved on: 
Wednesday, November 8, 2023
Science, Accel-KKR, Entrepreneurship, Growth, Partnership, Patient, Pharma, Fine chemical, Pharmaceutical industry, Financial adviser, Nordic Capital, Health care

IntegriChain delivers pharma's only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy.

Key Points: 
  • IntegriChain delivers pharma's only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy.
  • Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
  • IntegriChain's integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability.
  • Josh Halpern, Co-Founder and CEO of IntegriChain, said: "We're pleased to have Nordic Capital as a new partner to support us on our journey.

IntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex Pharmaceuticals

Retrieved on: 
Tuesday, November 7, 2023
Gene editing, FDA, Janssen, Alexion, Hematology, Partner (business rank), Courage, CRISPR, Conference, Entrepreneurship, Access, Senior, Townsend, Commercialization, Gamer, Boehringer Ingelheim, Paradox Access Solutions, Partnership, Market access, Cystic fibrosis, Service, Vertex Pharmaceuticals, Patient, Alexion Pharmaceuticals, Memory, Pharmaceutical industry, Fine chemical, Management, Vertex

PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the winners of its annual customer awards today at the Access Insights Conference, co-hosted with Blue Fin Group. IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend, Director of Distribution Strategy, at Vertex Pharmaceuticals. IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine, the Lighthouse Award to Alexion Pharmaceuticals, and the Zero to Launch Award to Tarsus Pharmaceuticals.

Key Points: 
  • IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend , Director of Distribution Strategy, at Vertex Pharmaceuticals .
  • IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine , the Lighthouse Award to Alexion Pharmaceuticals , and the Zero to Launch Award to Tarsus Pharmaceuticals .
  • The Tina Patel Bright Light Award is presented in memory of Tina Patel, Vice President, Market Access Marketing, for Boehringer Ingelheim.
  • The Tinal Patel Shining Light Award: Patrick Townsend, Vertex Pharmaceuticals
    Townsend leads distribution strategy at Vertex.

Key Pharma Commercialization Experts to Converge at Access Insights Conference 2023

Retrieved on: 
Tuesday, October 10, 2023
Benchmark, Pharmacy, Specialty pharmacy, ARCH Venture Partners, Pharma, Retail, GTN, Nautic Partners, Entrepreneurship, Martin PBM Mariner, BRG, New Model Union, Doctor of Pharmacy, Conference, Pharmaceutical industry, Management

PHILADELPHIA, Oct. 10, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the final agenda for next month's Access Insights Conference 2023, co-hosted with Blue Fin Group. The Access Insights Conference will be held November 6-8, 2023, at the JW Marriott Orlando Bonnet Creek. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature key industry speakers, exclusive ICyte Benchmark data, and strategic and tactical best practices for data-driven patient access and therapy commercialization. Sponsoring the conference are key Pharma service providers: Asembia, AssistRx, BRG, ConnectiveRx, EntityRisk, Pharmaceutical Commerce, Phil, Redi.Health, and Turquoise Health. Details and registration for the conference can be found here.

Key Points: 
  • PHILADELPHIA, Oct. 10, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the final agenda for next month's Access Insights Conference 2023, co-hosted with Blue Fin Group.
  • The Access Insights Conference will be held November 6-8, 2023, at the JW Marriott Orlando Bonnet Creek.
  • Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature key industry speakers, exclusive ICyte Benchmark data, and strategic and tactical best practices for data-driven patient access and therapy commercialization.
  • Sponsoring the conference are key Pharma service providers: Asembia , AssistRx , BRG , ConnectiveRx , EntityRisk , Pharmaceutical Commerce , Phil , Redi.Health , and Turquoise Health .

IntegriChain Expert to Speak on the Inflation Reduction Act at MDRP Summit

Retrieved on: 
Tuesday, September 12, 2023
IRA, Medicaid Drug Rebate Program, Inflation, Comment, Inflation Reduction Act of 2022, Takeda Pharmaceutical Company, Pharmaceutical industry, Pharma

Jeff Baab, Vice President of Operational Consulting, IntegriChain

Key Points: 
  • Jeff Baab, Vice President of Operational Consulting, IntegriChain
    Judd Caulfield, Lead Counsel of the Oncology Business Unit, Takeda Pharmaceuticals
    During this session, these IRA subject matter experts will explore the ongoing and future ramifications of the Inflation Reduction Act.
  • They will review where are in the process of operationalizing the IRA and what has happened since the most recent comment period.
  • They will also share insights into the selection of drugs up for negotiation and why they were selected.
  • With 80% of Pharma now reconsidering R&D of new products because of the IRA, these experts will discuss potential impacts and issues.